The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mutation promotes tumorigenesis. Recently, a HER2 splice variant lacking exon-16 (Δ16HER2) has been detected in human breast carcinomas. This alternative protein, a normal byproduct of HER2, has an incr...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3084693?pdf=render |
| _version_ | 1811202257745608704 |
|---|---|
| author | Cristina Marchini Federico Gabrielli Manuela Iezzi Santa Zenobi Maura Montani Lucia Pietrella Cristina Kalogris Anna Rossini Valentina Ciravolo Lorenzo Castagnoli Elda Tagliabue Serenella M Pupa Piero Musiani Paolo Monaci Sylvie Menard Augusto Amici |
| author_facet | Cristina Marchini Federico Gabrielli Manuela Iezzi Santa Zenobi Maura Montani Lucia Pietrella Cristina Kalogris Anna Rossini Valentina Ciravolo Lorenzo Castagnoli Elda Tagliabue Serenella M Pupa Piero Musiani Paolo Monaci Sylvie Menard Augusto Amici |
| author_sort | Cristina Marchini |
| collection | DOAJ |
| description | Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mutation promotes tumorigenesis. Recently, a HER2 splice variant lacking exon-16 (Δ16HER2) has been detected in human breast carcinomas. This alternative protein, a normal byproduct of HER2, has an increased transforming potency compared to wild-type (wt) HER2 receptors. To examine the ability of Δ16HER2 to transform mammary epithelium in vivo and to monitor Δ16HER2-driven tumorigenesis in live mice, we generated and characterized a mouse line that transgenically expresses both human Δ16HER2 and firefly luciferase under the transcriptional control of the MMTV promoter. All the transgenic females developed multifocal mammary tumors with a rapid onset and an average latency of 15.11 weeks. Immunohistochemical analysis revealed the concurrent expression of luciferase and the human Δ16HER2 oncogene only in the mammary gland and in strict correlation with tumor development. Transgenic Δ16HER2 expressed on the tumor cell plasma membrane from spontaneous mammary adenocarcinomas formed constitutively active homodimers able to activate the oncogenic signal transduction pathway mediated through Src kinase. These new transgenic animals demonstrate the ability of the human Δ16HER2 isoform to transform "per se" mammary epithelium in vivo. The high tumor incidence as well as the short latency strongly suggests that the Δ16HER2 splice variant represents the transforming form of the HER2 oncoprotein. |
| first_indexed | 2024-04-12T02:37:00Z |
| format | Article |
| id | doaj.art-edf05977323b4ac0ad6313f164920140 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T02:37:00Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-edf05977323b4ac0ad6313f1649201402022-12-22T03:51:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0164e1872710.1371/journal.pone.0018727The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.Cristina MarchiniFederico GabrielliManuela IezziSanta ZenobiMaura MontaniLucia PietrellaCristina KalogrisAnna RossiniValentina CiravoloLorenzo CastagnoliElda TagliabueSerenella M PupaPiero MusianiPaolo MonaciSylvie MenardAugusto AmiciSeveral transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mutation promotes tumorigenesis. Recently, a HER2 splice variant lacking exon-16 (Δ16HER2) has been detected in human breast carcinomas. This alternative protein, a normal byproduct of HER2, has an increased transforming potency compared to wild-type (wt) HER2 receptors. To examine the ability of Δ16HER2 to transform mammary epithelium in vivo and to monitor Δ16HER2-driven tumorigenesis in live mice, we generated and characterized a mouse line that transgenically expresses both human Δ16HER2 and firefly luciferase under the transcriptional control of the MMTV promoter. All the transgenic females developed multifocal mammary tumors with a rapid onset and an average latency of 15.11 weeks. Immunohistochemical analysis revealed the concurrent expression of luciferase and the human Δ16HER2 oncogene only in the mammary gland and in strict correlation with tumor development. Transgenic Δ16HER2 expressed on the tumor cell plasma membrane from spontaneous mammary adenocarcinomas formed constitutively active homodimers able to activate the oncogenic signal transduction pathway mediated through Src kinase. These new transgenic animals demonstrate the ability of the human Δ16HER2 isoform to transform "per se" mammary epithelium in vivo. The high tumor incidence as well as the short latency strongly suggests that the Δ16HER2 splice variant represents the transforming form of the HER2 oncoprotein.http://europepmc.org/articles/PMC3084693?pdf=render |
| spellingShingle | Cristina Marchini Federico Gabrielli Manuela Iezzi Santa Zenobi Maura Montani Lucia Pietrella Cristina Kalogris Anna Rossini Valentina Ciravolo Lorenzo Castagnoli Elda Tagliabue Serenella M Pupa Piero Musiani Paolo Monaci Sylvie Menard Augusto Amici The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS ONE |
| title | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| title_full | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| title_fullStr | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| title_full_unstemmed | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| title_short | The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. |
| title_sort | human splice variant δ16her2 induces rapid tumor onset in a reporter transgenic mouse |
| url | http://europepmc.org/articles/PMC3084693?pdf=render |
| work_keys_str_mv | AT cristinamarchini thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT federicogabrielli thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT manuelaiezzi thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT santazenobi thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT mauramontani thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT luciapietrella thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT cristinakalogris thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT annarossini thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT valentinaciravolo thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT lorenzocastagnoli thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT eldatagliabue thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT serenellampupa thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT pieromusiani thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT paolomonaci thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT sylviemenard thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT augustoamici thehumansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT cristinamarchini humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT federicogabrielli humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT manuelaiezzi humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT santazenobi humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT mauramontani humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT luciapietrella humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT cristinakalogris humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT annarossini humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT valentinaciravolo humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT lorenzocastagnoli humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT eldatagliabue humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT serenellampupa humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT pieromusiani humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT paolomonaci humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT sylviemenard humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse AT augustoamici humansplicevariantd16her2inducesrapidtumoronsetinareportertransgenicmouse |